BrainsWay Expands Mental Health Treatment Across the U.S.
BrainsWay Expands Mental Health Treatment Across the U.S.
BrainsWay Ltd. (NASDAQ: BWAY), a pioneering firm in noninvasive neurostimulation therapies, has marked a significant milestone with an ambitious expansion of its Deep TMS™ platform on the East Coast. The announcement came as the company confirmed an order of 14 new Deep TMS systems from a large enterprise network dedicated to mental health care. This order not only emphasizes BrainsWay's growing influence but also solidifies its position as a go-to provider among health practitioners.
CEO Comments on Expansion Strategy
“We are enthusiastic about enhancing the accessibility of Deep TMS therapy across the East Coast,” stated Hadar Levy, BrainsWay’s Chief Executive Officer. The order reflects a firm commitment to ushering in technologically advanced treatment options that benefit patients. Levy highlighted that nurturing relationships with diverse mental health organizations is crucial for achieving sustainable growth.
Current Success and Installed Base
As of mid-2024, BrainsWay boasts an installed base of over 1,200 Deep TMS systems across various locations. This extensive reach showcases the effectiveness and acceptance of this innovative treatment modality in addressing complex mental health disorders.
About Deep TMS Therapy
Deep Transcranial Magnetic Stimulation (Deep TMS™) represents a groundbreaking approach in treating mental health disorders such as major depressive disorder, obsessive-compulsive disorder, and smoking addiction. BrainsWay is proudly acknowledged for being the first company in the TMS sector to obtain FDA clearance for multiple indications, backed by substantial clinical research proving its efficacy. The technology utilizes magnetic fields to stimulate targeted areas of the brain, offering hope to patients seeking alternative treatment options.
Commitment to Continued Research and Development
BrainsWay is committed to advancing the science of neurostimulation. The company actively engages in clinical trials focusing on various psychiatric and neurological conditions. With its ongoing studies, BrainsWay aims to broaden treatment applications and reaffirm its leadership position in the neurostimulation field.
Building Awareness and Access
Founded in 2003 with headquarters in Burlington, MA, and Jerusalem, Israel, BrainsWay continues to work towards increasing global awareness regarding Deep TMS therapy. By ensuring greater accessibility, the company aspires to make a real difference in the lives of individuals battling mental health challenges.
Engagement with Investors and Stakeholders
The success of BrainsWay is attributed to its dedicated team and the ongoing engagement with investors and stakeholders. The company emphasizes transparency and is committed to updating its partners about significant developments, like the recent expansion efforts.
Frequently Asked Questions
What is Deep TMS therapy?
Deep TMS therapy is a noninvasive treatment that uses magnetic fields to stimulate specific areas in the brain, primarily aimed at treating mental health disorders.
How has BrainsWay expanded its reach recently?
BrainsWay has expanded its presence in the U.S. by securing a large order for 14 Deep TMS systems from an enterprise network focused on mental health.
What are the FDA-cleared indications for Deep TMS?
The FDA has cleared Deep TMS for several conditions including major depressive disorder, obsessive-compulsive disorder, and smoking addiction.
Where can I learn more about BrainsWay?
For the latest updates and information about BrainsWay, you can visit their official website.
How many Deep TMS systems are currently installed?
As of June 30, 2024, BrainsWay had installed over 1,215 Deep TMS systems worldwide.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Exploring Talkroute: The Ideal Virtual Phone Solution for Business
- Discover the New Chambray Townhome Community from Toll Brothers
- Securities Class Action Filed for Allarity Therapeutics (ALLR) Investors
- Precigen Focuses on Innovative Therapies at Upcoming Healthcare Event
- Northwest Urgent Care Expands Reach with Arizona Acquisition
- PAVmed Strengthens Position for Nasdaq Compliance Reinstatement
- Genius Group Cancels Meeting And Expands Strategic Initiatives
- Innovative Immunotherapy Institute Launches to Combat Cancer
- Unlocking the Benefits of Costco’s Executive Membership
- Understanding the Recent Performance of Recruit Holdings Co.
Recent Articles
- Exploring the Growth Trends in the Inflatable Boat Market
- Insights from the Latest Treasury Bills Auction Results
- Psyence Biomed Achieves Milestones in Psychedelic Research
- Mattr Corp. Completes Strategic Agreement with Vallourec
- Container One Launches New Refrigerated Shipping Containers
- Checkpoint Therapeutics Shares Promising Data for Cosibelimab
- Mattr Corp Finalizes Sale of Brazilian Pipe Coating Segment
- Insider Buying Trends: Notable Penny Stocks to Watch Right Now
- Lingerfelt Celebrates 100% Occupancy at Ashton Logistics Park
- Jack Brennan Appointed Managing Principal for Midwest Growth
- Federal Realty Investment Trust Celebrates Workplace Excellence
- Three Promising Stocks to Watch in Tech and Telecom This Quarter
- Atlas Engineered Products Completes Due Diligence for Acquisition
- New Insights from CEL-SCI's Multikine Study on Cancer Survival Rates
- NG Energy International Launches CPF at Sinu-9 for Gas Production
- Vecima Networks Welcomes Judd Schmid as New CFO
- FPX Nickel Launches Comprehensive Study for Major Refinery Project
- Sterling Bancorp Moves Forward with Sale and Dissolution Plans
- Vizsla Silver Secures $65 Million for Panuco Project Expansion
- SunCar Technology's Revenue Growth Leads with e-Insurance Surge
- Gilat Satellite Networks Wins Major Contracts Over $5M
- Royal Caribbean Group's Strategic Move: Refinancing Plans Unveiled
- UAE BioTech Symposium: A New Dawn for Biotech Innovation
- Understanding the Benefits of Homeownership Over Renting
- Labcorp Expands Diagnostic Services with Strategic Acquisition
- Explore Investment Opportunities in Soligenix's Upcoming Webinar
- Federal Realty Investment Trust Achieves Top Workplace Recognition
- Wendy's Company Welcomes New Leadership in Legal and Operations
- Piedmont Natural Gas's New Rate Agreement and Growth Outlook
- Jazz Pharmaceuticals Unveils Promising Zanidatamab Data
- Victra's Recent Tender Offer for Senior Secured Notes Explained
- Shockwave Medical Launches Groundbreaking E8 Catheter in U.S.
- BlueNord ASA Holds Digital Extraordinary General Meeting
- BofA Increases Thermo Fisher Stock Target to $675 Amid Growth Signs
- InspireMD Advances with FDA Submission for Carotid Solutions
- Breakthrough Phase 2 Results for Evaxion's Cancer Vaccine
- Cullinan Therapeutics Advances Innovative Lupus Treatment
- AstraZeneca's Promising Breakthrough in Liver Cancer Treatment
- Compass Therapeutics Gets Boost from Ladenburg to Buy Rating
- Summit Therapeutics Receives Positive Analyst Upgrades Amid Data
- Tonix Pharmaceuticals Advances Vaccine Development for mpox
- Instil Bio's Stock Value Surges on Promising Cancer Drug News
- Bausch + Lomb Considers Sale Amid Financial Challenges
- Credit Agricole CIB Shifts Focus to Carbon Trading
- Premarket Stocks Surge with Notable Gains for Pfizer and Intel
- Investors Weigh Options Ahead of Major Federal Rate Decision
- QubitsCube Pledges Significant Contribution to Charity Initiatives
- Cookpad Revolutionizes Crypto Project Development with Ease
- Adeia and LG Electronics: A Lasting Partnership in Media IP
- Alliance Trust PLC Reveals Recent Net Asset Values